|
1
|
Manning M, Stoev S, Chini B, Durroux T,
Mouillac B and Guillon G: Peptide and non-peptide agonists and
antagonists for the vasopressin and oxytocin V1a, V1b, V2 ant OT
receptors: research tools and potential therapeutic agents. Prog
Brain Res. 170:473–512. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Manning M, Misicka A, Olma A, Bankowski K,
Stoev S, Chini B, Durroux T, Mouillac B, Corbani M and Guillon G:
Oxytocin and vasopressin agonists and antagonists as research tools
and potential therapeutics. J Neuroendocrinol. 24:609–628. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
North WG, Fay MJ and Du J: MCF-7 breast
cancer cells express normal forms of all vasopressin receptors plus
an abnormal V2R. Peptides. 20:837–842. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ripoll GV, Giron S, Krzymuski MJ, Hermo
GA, Gomez DE and Alonso DF: Antitumor effects of desmopressin in
combination with chemotherapeutic agents in a mouse model of breast
cancer. Anticancer Res. 28:2607–2611. 2008.PubMed/NCBI
|
|
5
|
Alonso DF, Ripoll GV, Garona J, Iannucci
NB and Gomez DE: Metastasis: recent discoveries and novel
perioperative treatment strategies with particular interest in the
hemostatic compound desmopressin. Curr Pharm Biotech. 12:1974–1980.
2011. View Article : Google Scholar
|
|
6
|
Cunningham BC and Wells JA:
High-resolution epitope mapping of hGH receptor interactions by
alanine-scanning mutagenesis. Science. 244:1081–1085. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beck-Sickinger AG, Wieland HA, Wittneben
H, Willim KD, Rudolf K and Jung G: Complete L-alanine scan of
neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with
distinguished conformations. Eur J Biochem. 225:947–958. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nicole P, Lins L, Rouyer-Fessard C, Drouot
C, Fulcrand P, Thomas A, Couvineau A, Martínez J, Brasseur R and
Laburthe M: Identification of key residues for interaction of
vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors
and development of a highly selective VPAC1 receptor agonist.
Alanine scanning and molecular modeling of the peptide. J Biol
Chem. 275:24003–24012. 2000. View Article : Google Scholar
|
|
9
|
Quartara L, Ricci R, Meini S, et al: Ala
scan analogues of HOE 140. Synthesis and biological activities. Eur
J Med Chem. 35:1001–1010. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nam J, Shin D, Rew Y and Boger DL: Alanine
scan of [L-Dap(2)]ramoplanin A2 aglycon: assessment of the
importance of each residue. J Am Chem Soc. 129:8747–8755. 2007.
|
|
11
|
Houghten RA: General method for the rapid
solid-phase synthesis of large numbers of peptides: specificity of
antigen-antibody interaction at the level of individual amino
acids. Proc Natl Acad Sci USA. 82:5131–5135. 1985. View Article : Google Scholar
|
|
12
|
Albericio F, Annis I, Royo M and Barany G:
Preparation and handling of peptides containing methionine and
cysteine. Fmoc Solid Phase Peptide Synthesis. A Practical Approach.
Chan WC and White PD: Oxford University Press Inc; New York, NY:
pp. 77–114. 2000
|
|
13
|
Czaplewski C, Kázmierkiewicz R and
Ciarkowski J: Molecular modeling of the human vasopressin V2
receptor/agonist complex. J Comp Aided Mol Des. 12:275–287. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iannucci NB, Ripoll GV, Garona J, Cascone
O, Ciccia GN, Gomez DE and Alonso DF: Antiproliferative effect of
1-deamino-8-D-arginine vasopressin analogs on human breast cancer
cells. Future Med Chem. 3:1987–1993. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kowalczyk W, Prahl A, Derdowska I,
Sobolewski D, Olejnik J, Zabrocki J, Borovicková L, Slaninová J and
Lammek B: Analogues of neurohypophyseal hormones, oxytocin and
arginine vasopressin, conformationally restricted in the N-terminal
part of the molecule. J Med Chem. 49:2016–2021. 2006. View Article : Google Scholar
|
|
16
|
North WG, Pai S, Friedmann A, Yu X, Fay M
and Memoli V: Vasopressin gene related products are markers of
human breast cancer. Breast Cancer Res Treat. 34:229–235. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Monstein HJ, Truedsson M, Ryberg A and
Ohlsson B: Vasopressin receptor mRNA expression in the human
gastrointestinal tract. Eur Surg Res. 40:34–40. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
North WG, Fay MJ, Longo KA and Du J:
Expression of all known vasopressin receptor subtypes by small cell
tumors implies a multifaceted role for this neuropeptide. Cancer
Res. 58:1866–1871. 1998.PubMed/NCBI
|
|
19
|
Terraube V, Pendu R, Baruch D, Gebbink MF,
Meyer D, Lenting PJ and Denis CV: Increased metastatic potential of
tumor cells in von Willebrand factor-deficient mice. J Thromb
Haemost. 4:519–526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mochizuki S, Soejima K, Shimoda M, Abe H,
Sasaki A, Okano HJ, Okano H and Okada Y: Effect of ADAM28 on
carcinoma cell metastasis by cleavage of von Willebrand factor. J
Natl Cancer Inst. 104:906–922. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Colgrave ML and Craik DJ: Thermal,
chemical and enzymatic stability of the cyclotide kalata B1: the
importance of the cyclic cystine knot. Biochemistry. 43:5965–5975.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Craik DJ, Cemazar M and Daly NL: The
cyclotides and related macrocyclic peptides as scaffolds in drug
design. Curr Opin Drug Discovery Devel. 9:251–260. 2006.PubMed/NCBI
|
